Format

Send to

Choose Destination
PLoS One. 2014 Feb 21;9(2):e87412. doi: 10.1371/journal.pone.0087412. eCollection 2014.

Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2.

Author information

1
Programa de Estudio y Control de Enfermedades Tropicales, Universidad de Antioquia, Medellín, Colombia.
2
Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia ; Laboratorio de Patología, Congregación Mariana, Medellin, Colombia.
3
Grupo de Virología, Universidad El Bosque, Bogotá, Colombia.
4
Molecular and Translational Medicine Group, Viral Vector Core and Gene Therapy of the Neuroscience's Group of Antioquia, Universidad de Antioquia, Medellín, Colombia ; Molecular and Translational Medicine Group, Universidad de Antioquia, Medellín, Colombia.
5
Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, United States.

Abstract

BACKGROUND:

It has been reported that treatment of DENV-infected cultures with Lovastatin (LOV), can affect viral assembly. The objective of this study was to evaluate the effect of LOV on the survival rate and viremia levels of DENV-2-infected AG129 mice.

METHODOLOGY/PRINCIPAL FINDINGS:

Mice were inoculated with 1 × 10(6) plaque-forming units (PFU/ml) of DENV-2 and treated with LOV (200 mg/kg/day). Pre-treatment with one or three doses of LOV increased the survival rate compared to untreated mice (7.3 and 7.1 days, respectively, compared to 4.8 days). Viremia levels also decreased by 21.8% compared to untreated mice, but only in the group administered three doses prior to inoculation. When LOV was administered after viral inoculation, the survival rate increased (7.3 days in the group treated at 24 hpi, 6.8 days in the group treated at 48 hpi and 6.5 days in the group treated with two doses) compared to the untreated group (4.8 days). Interestingly, the serum viral titer increased by 24.6% in mice treated at 48 hpi with a single dose of LOV and by 21.7% in mice treated with two doses (at 24 and 48 hpi) of LOV compared to untreated mice. Finally histopathological changes in the liver and spleen in infected and untreated mice included massive extramedullary erythropoiesis foci and inflammatory filtration, and these characteristics were decreased or absent in LOV-treated mice.

CONCLUSIONS/SIGNIFICANCE:

Our results suggest that the effect of LOV on viremia depends on the timing of treatment and on the number of doses administered. We observed a significant increase in the survival rate in both schemes due to a delay in the progression of the disease. However, the results obtained in the post-treatment scheme must be handled carefully because this treatment scheme increases viremia and we do not know how this increase could affect disease progression in humans.

PMID:
24586275
PMCID:
PMC3931612
DOI:
10.1371/journal.pone.0087412
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center